are glp 1 still available New project announcement: HHS‑OIG is taking a closer look at FDA's oversight of compounded GLP‑1 drugs. Although shortages ended in 2025, some facilities may be producing these drugs at scale. Our Understanding GLP-1 Drugs: Cost, Safety,

Among firms with 200 or more employees that do not provide coverage for GLP-1 agonists primarily for weight loss, 62% say that they are not likely to begin covering these medications for weight loss within the next twelve months, 23% say that they are somewhat likely to do so, 3% say that they are very likely to do so, and 11% do not know

This is likely due to structural differences: ipamorelin Aib/D-2-Nal backbone produces a different binding mode at GHS-R1a that may favor specific downstream signaling pathways (biased agonism) compared to the His/D-Trp backbone of GHRP-6

These findings were consistent in the per-protocol analysis (estimated mean difference [95% CI] for dulaglutide versus placebo 492 mL [811, 173]) and in the sensitivity analyses adjusting for adverse effects at the beginning of the evaluation visit (474 mL [812, 136]) or anytime during the evaluation visit (428 mL [850, 6])

It was approved on July 24 for the temporary relief of pain and will be available without a prescription